Chardan Capital Expects Weaker Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Research analysts at Chardan Capital reduced their FY2025 EPS estimates for shares of Krystal Biotech in a report issued on Tuesday, April 29th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of $6.15 per share for the year, down from their previous estimate of $7.49. Chardan Capital has a "Buy" rating and a $219.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. Chardan Capital also issued estimates for Krystal Biotech's FY2026 earnings at $9.13 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million.

KRYS has been the topic of several other research reports. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday. Guggenheim cut their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $218.63.

Krystal Biotech Stock Performance

KRYS stock traded down $4.09 during midday trading on Friday, reaching $135.38. 237,003 shares of the company were exchanged, compared to its average volume of 296,860. The stock's 50-day simple moving average is $173.96 and its 200 day simple moving average is $170.88. Krystal Biotech has a 1-year low of $133.13 and a 1-year high of $219.34. The company has a market cap of $3.91 billion, a price-to-earnings ratio of 46.04 and a beta of 0.79.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. Norges Bank bought a new position in shares of Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. lifted its holdings in shares of Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after buying an additional 141,400 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Krystal Biotech by 50,249.4% during the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock valued at $21,878,000 after purchasing an additional 121,101 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Krystal Biotech during the fourth quarter worth about $15,989,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).